Neurocrine Biosciences | NBIX - Selling And Administration Expenses


Neurocrine Biosciences reported $301.8M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
AbbVie USD 3.89B 325M Dec/2025
Acadia Pharmaceuticals USD 146.73M 21.82M Dec/2025
Agios Pharmaceuticals USD 42.97M 1.7M Dec/2025
ALKERMES USD 187.2M 15.43M Dec/2025
Alnylam Pharmaceuticals USD 285.06M 22.47M Dec/2025
Amgen USD 1.94B 237M Dec/2025
Biogen USD 545.2M 38.6M Sep/2025
BioMarin Pharmaceutical USD 322.21M 98.79M Dec/2025
Cytokinetics USD 91.72M 67.02M Dec/2025
Enanta Pharmaceuticals USD -1.05 0.31 Dec/2024
Exelixis USD 123.02M 19.9M Dec/2025
Gilead Sciences USD 1.78B 425M Dec/2025
Halozyme Therapeutics USD 64.64M 27.11M Dec/2025
Incyte USD 390.41M 61.33M Dec/2025
Ionis Pharmaceuticals USD 130M 43.43M Dec/2025
Nektar Therapeutics USD 10.17M 10.17M Dec/2025
Neurocrine Biosciences USD 301.8M 10.2M Dec/2025
Pfizer USD 4.08B 894M Dec/2025
Prothena USD 7.65M 5.59M Dec/2025
Regeneron Pharmaceuticals USD 775M 117.2M Dec/2025
Repligen USD 74.36M 703K Dec/2025
Rigel Pharmaceuticals USD 27.04M 1M Sep/2024
Sarepta Therapeutics USD 105.38M 28.27M Dec/2025
Teva Pharmaceutical Industries USD 1.12B 147M Dec/2025
Ultragenyx Pharmaceutical USD 89M 2.38M Dec/2025
Vertex Pharmaceuticals USD 487M 41.9M Dec/2025
Xoma USD 11M 2.54M Jun/2024